Chronos Archive seal

Review checklist: Madam C. J. Walker (HR-ET019)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the confirmation of hypertension by ambulatory monitoring, the CKD G3a A2 staging with the race-free eGFR and prior results for chronicity, losartan titration and the creatinine and potassium checks, empagliflozin without diabetes, the statin chosen at intermediate risk, the sick-day handling during gastroenteritis, and the APOL1 discussion.
provenance reviewnot_startedSources: the Indiana Historical Society, 64 Parishes, the National Archives, the National Women's History Museum, the Gale Women in World History entry, the Lemelson Center, A'Lelia Bundles's site, and a passage of her biography quoted in Wikipedia. The NMAAHC pages, the New York Times obituary and the biography itself could not be read.
safe messaging reviewnot_startedNo mental health claim is made; the mood screen is synthetic and below the threshold for a safety assessment. Her history is told with attention to slavery, poverty and the forms of address she refused, without stereotype; her work is treated as hers to direct.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. She died in 1919, so the rule does not apply. The record keeps to published biographies and adds one ordinary sick visit that bears on her medicines.
  2. Name. The display name is “Madam C. J. Walker,” the name she chose and kept. “Madam” is a title and “C. J.” are the initials of her husband Charles Joseph Walker, so splitting the display name at the last space would code “Madam C. J.” as given names. `identity.name_parts` therefore codes her legal name as given “Sarah,” family “Walker” (the Gale entry lists “Sarah Walker” among her names); FHIR `name.text` keeps the display name. The notes call her “Madam Walker,” the form of address she chose (SOC-007, linked to CLM-0004). “Walker” alone appears in other records and is not an alias; the alias “Sarah Breedlove,” her birth name, appears in no other record.
  3. What could not be verified and was left out. The National Museum of African American History and Culture pages, the New York Times obituary, and On Her Own Ground itself could not be read; her physicians’ words are used only through the passage quoted from the biography. A personal physician said to have attended her death, and her reported last words, appear only in a local history blog and a novel-like biography, so they are not used. No fetched source dates a diagnosis of high blood pressure in 1916: the Gale entry records hypertension and the Hot Springs rest cure in 1916 without a date for the diagnosis, and the dated diagnosis (nephritis worsened by hypertension) is November 1917. The roster note “advised to rest in 1916 to 1919” is therefore represented by CLM-0006 and CLM-0007, not by a separate claim. The 1917 East St. Louis delegation to the White House is not used, since the fetched National Archives page documents only the petition.
  4. Conflicts. Her marriage to Charles Joseph Walker is dated January 4, 1906 (Gale), 1906 (64 Parishes) or 1905 (National Archives); CLM-0004 gives 1906 with the alternative. Her move to Villa Lewaro is 1917 (64 Parishes) or 1918 (other accounts); CLM-0008 keeps both. The cause of death is chronic interstitial nephritis (Gale), kidney failure (National Women’s History Museum, Lemelson Center), or high blood pressure and kidney failure (Indiana Historical Society); CLM-0009 records them together. The quoted biography passage gives 2001 (Gale) or 2002 (the edition Wikipedia cites); the source uses 2001.
  5. Index age and dates. The index visit on February 9, 2026 maps to February 9, 1917, when she was 49: the year after the Hot Springs rest cure and nine months before the November 1917 diagnosis of nephritis worsened by hypertension. The roster suggested about 48 or 49; 49 is the age at the only dated diagnosis. Synthetic date of birth December 23, 1976 (shift 109 years). The chronic-care visits on February 23, March 9, April 27 and August 17, the sick visit on April 13, the preventive visit on June 8 and the mammogram on June 22, 2026 map to the same days of 1917, before the nephritis diagnosis, the Battle Creek stay and the move to Villa Lewaro, and none falls on the July 1917 protest days. She is 49 throughout. Past medical history includes only the hair loss (1904) and the hypertension with the Hot Springs rest cure (1916); family history records only that both parents died when she was a child, cause not recorded. The nephritis claim (CLM-0007) is after the index date and is linked only to its timeline event, the kidney problems recorded at two weeks, and the referral step.
  6. Synthetic clinical picture. Hypertension is documented; its stage, the ambulatory and home readings, the left ventricular hypertrophy, retinopathy, kidney findings, laboratory values, imaging and medicines are synthetic. Following the presenting-problem pattern, intake records elevated blood pressure (R03.0) and albuminuria with reduced eGFR (R80.9), both resolved at two weeks when ambulatory monitoring confirmed stage 2 hypertension and the repeat tests, the year-old results and the ultrasound established CKD G3a A2 (I12.9 and N18.31 recorded then). The eGFR is stated as CKD-EPI 2021 without a race term in every label and note; the older CKD-EPI 2009 equation with a race coefficient would have reported about 60, which is stated once as a teaching point. The 10-year ASCVD risk (7.9%) is calculated from her synthetic values with the Pooled Cohort Equations for Black women, and the 5-year KFRE (1.6%, then 1.7%) with the 4-variable North American equation. Qualitative results (urinalysis, ECG, ambulatory monitoring, ultrasound, echocardiogram, fundi, hepatitis and HIV tests, mammogram, HPV and stool tests) appear only in note text. Height (163 cm) and weights are synthetic.
  7. Race and medicine. The record is written to avoid race-based medicine: the eGFR has no race coefficient; the first medicine is chosen for albuminuric CKD (an ARB, with the ACE inhibitor’s cough the deciding factor for a public speaker), not for her race; APOL1 genotyping is offered with counseling as her choice, explained as information that would not change treatment, and she declines for now. Her history of hair loss is told as her biographers tell it, as a condition shared by many Black women of her time, in an era of hard labor, poor diet and no indoor plumbing.
  8. Work and rest, the teaching contrast. Her documented advice was to rest; she did not slow down. In the modern episode no clinician tells her to slow down. The risks are stated plainly, the medicines are chosen and titrated to reach the goal, and the plan fits her travel: a home monitor that travels, medicines at home time across time zones, a sick-day card, video visits and laboratory days at home. Two missed laboratory checks are the realistic cost of her schedule and are recorded honestly.
  9. Food. The diet plan builds on what she eats: a salt-free version of her seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts, ordering strategies for banquets, and water on travel days; no potassium-based salt substitutes on losartan. Her real diet was not researched; the diet history is synthetic.
  10. Real people. Her parents, her first husband, Charles Joseph Walker, her daughter, Annie Turnbo Malone (not named in claims) and Dr. George Sauer appear only in documented history. Her daughter is mentioned in the modern social history only as part of her family and has no role. No modern decision, statement or health fact is attributed to any real person.
  11. Sick visit. A same-day visit for viral gastroenteritis after a sales convention, chosen because it tests the sick-day rules for losartan and empagliflozin in CKD: she held both correctly, creatinine rose from 1.29 to 1.46 mg/dL (below the acute kidney injury threshold) and recovered, and the medicines were restarted after a day of normal eating. It insinuates no real diagnosis.
  12. Preventive visit. A periodic adult preventive visit at 49 (CPT 99396 with 99497 in plain text). Judgment calls: PCV20 because the CDC lists chronic renal failure as an indication, interpreted to include CKD G3a; hepatitis B vaccination because her screening showed no immunity; a primary HPV test and a mailed stool test, her choices to fit her travel; zoster deferred until 50; osteoporosis screening not indicated before menopause without risk factors.
  13. Focused visits. The four chronic-care follow-ups (two weeks with the consultation, four weeks, eleven weeks and six months) are documented as focused visits on the CMID hypertension, chronic kidney disease, hyperlipidemia and depression monographs, the 2025 AHA/ACC guideline, KDIGO 2024 and KDIGO 2021. One deviation row records two missed checks instead of invented results: the potassium and creatinine due two to four weeks after the losartan increase (missed on a three-week tour) and the panel planned a week after the gastroenteritis (missed on another trip). The sick-visit panel and the eleven-week results showed no harm (potassium 4.9 then 4.7 mmol/L; creatinine 1.46 then 1.31 mg/dL), and the corrective action was to book every laboratory check on a home day before trips are scheduled (INT-012). Synthetic findings introduced: the echocardiogram (mild concentric LVH, ejection fraction 60%), negative hepatitis and HIV tests, and her decision on APOL1 testing.
  14. Consultation. The nephrology referral and consultation by Desmond Achterberg, MD (a fictional consultant), on the day of the two-week visit, are S. The consultant answers the six referral questions in line with what the record shows afterwards: hypertensive kidney disease most likely, no biopsy; losartan titrated to 100 mg (done at four weeks) and amlodipine next (added at eleven weeks); a goal below 130/80 toward a systolic of 120 (122/76 at six months); empagliflozin without diabetes; potassium and creatinine two to four weeks after each change (once missed, see above) and then every six months; APOL1 testing offered as her choice (declined at six months); hepatitis and HIV tests (negative) and hepatitis B vaccination (given); KFRE 1.6%; and review in about six months by video, booked at the last visit.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-04-27
Progress note 05 (C-CDA)
Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free)Two to four weeks after starting or increasing losartan or empagliflozin; then every six monthsMissed: the panel due two to four weeks after the losartan increase was not done because she was on a three-week tour with no laboratory day booked, and the panel planned a week after the gastroenteritis was missed for another trip. No harm judging by the sick-visit panel (potassium 4.9 mmol/L, creatinine 1.46 mg/dL while volume depleted) and today's results (potassium 4.7 mmol/L, bicarbonate 24 mmol/L, creatinine 1.31 mg/dL, eGFR 50). Corrective action: her office books each laboratory check on a home day before trips are scheduled (INT-012)

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-02-23
Progress note 02 (C-CDA)
ImagingEchocardiogramOrderedBooked for the next visit
2026-06-08
Progress note 06 (C-CDA)
PreventionBreast cancer screeningOrderedMammogram every two years from 40; booked in two weeks on a day she is home
2026-06-08
Progress note 06 (C-CDA)
PreventionColorectal cancer screeningOrderedFrom 45; stool immunochemical test yearly, her choice so that she can mail it while traveling; colonoscopy discussed

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-02-09Creatinine1.22 mg/dL (high)High
2026-02-09eGFR (CKD-EPI 2021, race-free)54 mL/min/1.73 m² (low)Low
2026-02-09Urine albumin-to-creatinine ratio286 mg/g (high)High
2026-02-09Total cholesterol250 mg/dL (high)High
2026-02-09LDL cholesterol174 mg/dL (high)High
2026-02-09HDL cholesterol46 mg/dL (low)Low
2026-02-09Triglycerides150 mg/dL (high)High
2026-02-23Urine albumin-to-creatinine ratio294 mg/g (high)High
2026-02-23Creatinine1.21 mg/dL (high)High
2026-02-23eGFR (CKD-EPI 2021, race-free)55 mL/min/1.73 m² (low)Low
2026-03-09Creatinine1.29 mg/dL (high)High
2026-03-09eGFR (CKD-EPI 2021, race-free)51 mL/min/1.73 m² (low)Low
2026-04-13Bicarbonate (total CO2)21 mmol/L (low)Low
2026-04-13Creatinine1.46 mg/dL (high)High
2026-04-13eGFR (CKD-EPI 2021, race-free)44 mL/min/1.73 m² (low)Low
2026-04-27Creatinine1.31 mg/dL (high)High
2026-04-27eGFR (CKD-EPI 2021, race-free)50 mL/min/1.73 m² (low)Low
2026-04-27Urine albumin-to-creatinine ratio176 mg/g (high)High
2026-04-27HDL cholesterol48 mg/dL (low)Low
2026-08-17Creatinine1.3 mg/dL (high)High
2026-08-17eGFR (CKD-EPI 2021, race-free)50 mL/min/1.73 m² (low)Low
2026-08-17Urine albumin-to-creatinine ratio128 mg/g (high)High